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Para ser grande, sê inteiro: nada 
Teu exagera ou exclui. 
Sê todo em cada coisa. Põe quanto és 
No mínimo que fazes. 
Assim em cada lago a lua toda 
Brilha, porque alta vive. 
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Abbreviation List 
ABC: Activities-specific Balance Confidence scale 
CNS: central nervous system 
DBS: deep brain stimulation 
DFA: detrended fluctuation analysis 
FOG: freezing of gait 
FOGQ: Freezing of Gait Questionnaire 
FR: Functional Reach scale 
GPi: globus pallidus internal 
HD: Huntington’s disease 
MPH: methylphenidate 
MRI scans: magnetic resonance imaging scans 
PAS: Parkinson-Activity-Scale 
PD: Parkinson’s disease  
PPN: pedunculopontine nucleus 
RAS: rhythmic auditory stimulation 
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STN: sub-thalamic nucleus 
TUG: Timed Up and Go scale 
UHDRS: Unified Huntington’s Disease Rating Scale 
UPDRS: United Parkinson’s Disease Rating Scale  
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VL: ventral lateral nuclei of thalamus 
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Abstract 
Movement disorders affect gait, which is one of the most disabling manifestations. Analyzing 
the brain circuits dependent on the basal ganglia (caudate, putamen, globus pallidus, 
subthalamic nucleus and substantia nigra), also responsible for organizing movement, we 
were closer to understand the neurophysiological basis of its operation, taking in account, 
particularly, the pattern of change of  neurotransmitters in each pathology. 
We considered the Parkinson's and Huntington's diseases as study models, which are 
characterized by cognitive, behavioral and motor symptoms, as a result of the underlying 
changes. They were considered in analogy, relating their pathophysiological mechanisms to 
the circuits of the basal ganglia, which allowed classifying their role in normal gait 
performance or disease. 
The evaluation of these diseases goes through different scales and experimental models, 
which are also intended to objectify and quantify changes in gait, as festination and freezing. 
This helps in implementing the pharmacological treatment, which appears still insufficient. In 
addition, there are techniques of physiotherapy and rehabilitation medicine. 
Therefore, making an updated review of the mechanisms underlying changes in gait in 
movement disorders, clarifying the role of different neurological structures involved in both 
the disease and in its absence, was the aim of this work. 
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Resumo 
As doenças do movimento afectam a marcha, sendo uma das manifestações mais 
incapacitantes. Analisando os circuitos cerebrais dependentes dos gânglios da base (caudado, 
putamen, globo pálido, substância negra e núcleo subtalâmico), também responsáveis pela 
organização da locomoção, ficámos mais perto de conhecer as bases neurofisiológicas do seu 
funcionamento, tendo em conta, nomeadamente, o padrão de alteração de neurotransmissores 
próprio de cada patologia. 
Consideraram-se a Doença de Parkinson e a Doença de Huntington como modelos de estudo, 
sendo caracterizadas por sintomatologia cognitiva, comportamental e motora, fruto das 
alterações subjacentes. Foram abordadas numa perspectiva de analogia, relacionando os seus 
mecanismos fisiopatológicos com os circuitos dos gânglios da base, o que permitiu classificar 
o seu papel no desempenho da marcha normal ou na doença. 
A avaliação destas doenças passa por diferentes escalas e modelos experimentais, que visam 
também quantificar e objectivar alterações da marcha como a festinação e o freezing. Este 
facto auxilia na implementação do tratamento farmacológico, o qual se apresenta ainda 
insuficiente. Como complemento existem técnicas de fisioterapia e medicina de reabilitação. 
Foi, por isso, objectivo deste trabalho fazer uma revisão actualizada dos mecanismos 
subjacentes às alterações da marcha nas doenças do movimento, clarificando o papel das 
diferentes estruturas neurológicas envolvidas tanto na doença como na ausência dela. 
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1. Introduction 
Gait disorders are very common in patients with Parkinson’s and Huntington’s diseases. This 
can lead to a huge tendency to fall (because of postural instability), with severe consequences 
on independence and quality of life, causing an increase in morbidity and mortality among 
these patients. For that reason, understanding the mechanisms underlying gait disorders is a 
major public health priority. Recent studies have confirmed the high rate and high risk of falls 
among these patients, which highlights the importance of a deeply knowledge in this area. 
The basal ganglia (BG) have a preponderant role in the initiation and modulation of 
movements, and constitute many loops that control motor, cognitive and behavioral functions. 
They integrate sensory and non-sensory, primary and secondary cortical information and give 
rise to specific directed fascicles that influence the cerebral cortex motor actions. 
There are several new approaches that modify this system, such as pharmacological treatment, 
deep brain stimulation and physical exercises. 
The aim of this review is to generalize these possibilities and make patients’ orientation 
easier. 
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2. Methods 
The basis of this work is an article search and narrative revision, using the most recent 
published bibliography, and the systematic revisions criteria, explained below.  
The main purpose of this review article is to analyze and summarize the existent studies about 
gait disorders in Parkinson’s and Huntington’s diseases, in order to help other investigations 
and offer a more convenient source of desired information. 
We did our investigation considering the 5S of Haynes model, which is a pyramid that 
includes: Systems, Summaries, Synopses, Syntheses and Studies (from the top to the base). 
Beginning with Summaries (because Systems is not used), we searched in DynaMed 
(www.ebscohost.com/dynamed), where we found one document about Parkinson’s disease 
and another about Huntington’s disease, both of them not related with gait. Then, we searched 
in UpToDate (www.uptodate.com), where we found the following documents: Clinical 
manifestations of Parkinson Disease; Gait disorders of elderly patients and Management of 
comorbid problems associated with Parkinson Disease, using the keywords “movement” and 
“Parkinson”. Similarly, with the keywords “gait” and “Parkinson”, the results were the same. 
On the other hand, using the keywords “movement” and “Huntington”, we found the 
document Huntington Disease: clinical features and diagnosis. Similarly, with the keywords 
“gait” and “Huntington”, the results were the same. 
Secondly, we searched for Synopses in ACP Journal Club (acpjc.acponline.org). We used the 
keywords “gait” and “Parkinson”, and we found 2 documents: Cueing training in the home 
improves gait-related mobility in Parkinson’s disease: the RESCUE trial and Anticholinergic 
drugs improve motor function and disability in Parkinson disease. In the same way, with the 
keywords “movement” and “Parkinson”, we came across the following documents: Practice 
Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an 
evidence-based review): report of the Quality Standards Subcommittee of the American 
Gait disorders in Parkinson’s and Huntington’s diseases 
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Academy of Neurology; Helicobacter pylori eradication and l-dopa absorption in patients 
with Parkinson disease and motor fluctuations; Practice corner: Sleepless in Sydney-ls 
valerian an effective alternative to benzodiazepines in the treatment of insomnia? and 
Gabapentin improved sensory and motor symptoms in the restless legs syndrome. Moreover, 
using the keywords “gait” and “Huntington”, as well as “movement” and “Huntington”, no 
documents were find. Then, we searched in Evidence-Based Medicine (ebm.bmj.com), and: 
with the keywords “movement” and “Parkinson” we discovered 55 documents; with the 
keywords “gait” and “Parkinson” we found 30 documents (7 repeated); with the keywords 
“movement” and “Huntington” we found 41 documents; and finally with the keywords “gait” 
and “Huntington” we discovered 16 documents (3 repeated). 
Thirdly, searching for Syntheses, in Cochrane Library (www.thecochranelibrary.com) we 
found 24 Cochrane reviews (selecting Physiotherapy for Parkinson’s disease: a comparison 
of techniques and Physiotherapy versus placebo or no intervention in Parkinson’s disease), 
with the keywords “movement” and “Parkinson”. Likewise, using the keywords “gait” and 
“Parkinson” we came across one document (Treadmill training for patients with Parkinson’s 
disease), with “movement” and “Huntington” we found 2 documents (Therapeutic 
interventions for symptomatic treatment in Huntington’s disease and Therapeutic 
interventions for disease progression in Huntington’s disease), and with “gait” and 
“Huntington” we discovered also 2 documents (Treatment of Huntington’s disease and 
Treatment of Huntington’s chorea with bromocriptine). In addition, to ameliorate the search, 
we used PubMed (www.pubmed.gov), with a methodological filter. In PubMed clinical 
queries, using the systematic reviews’ filter, we can find meta-analyses, reviews of clinical 
trials, evidence-based medicine, consensus and guidelines. To use the filter, we have to assess 
PubMed tools, clinical queries and then the keywords and the systematic reviews’ filter. 
Using the keywords “(gait disorder OR gait disorders) AND (parkinson OR parkinsons)”, we 
Gait disorders in Parkinson’s and Huntington’s diseases 
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obtained 30 references; then with the following limits: 2006 till December 2011, English 
language and only studies in humans, the results diminished to 18 references. Similarly, with 
the keywords “(movement disorder OR movement disorders) AND (parkinson OR 
parkinsons)”, we obtained 579 references, reducing to 270 with the mentioned limits. 
Correspondingly, using the keywords “(gait disorder OR gait disorders) AND (huntington OR 
huntingtons)”, we came across 2 references, reducing to 0 with the same limits. At last, using 
the keywords “(movement disorder OR movement disorders) AND (huntington OR 
huntingtons)”, we found 61 documents, reducing to 28 with the same limits. Then, the 
document selection was made considering the scientific journal quotation and the number of 
its references. 
Finally, searching for Studies in PubMed (www.pubmed.gov), we used also keywords and 
MeSH (Medical Subject Headings). With “Gait Disorders, Neurologic” and “Parkinson 
Disease”, we came across 234 references, withdrawing to 170 with the application of the 
limits mentioned above. With “Movement Disorders” and “Parkinson Disease”, we found 
8856 references and 1753 review articles, diminishing to 1102 references and 193 review 
articles with the limits. There are 22 repeated references between these two ways of 
searching: gait versus movement, only in Parkinson Disease. Then, using the keywords “Gait 
Disorders, Neurologic” and “Huntington Disease”, we discovered 12 references, reducing to 8 
with the same limits. At last, using “Movement Disorders” and “Huntington Disease”, we 
found 3536 references, withdrawing to 1281 references and 227 review articles with the 
limits. There are 8 repeated articles between these two ways of searching: gait versus 
movement, only in Huntington Disease. Considering both the diseases, there are 3 repeated 
articles. Afterward, the document selection was made considering the scientific journal 
quotation and the number of its references. 
Besides the articles, we also used 2 chapters of 2 books, mentioned in the References section. 
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3. Results 
 
3.1. The role of the basal ganglia in movements 
Motor regions of the cortex and brainstem contain upper motor neurons that initiate 
movement by controlling the activity of local circuit and lower motor neurons in the 
brainstem and spinal cord (pyramidal tract). 
Important regions in motor control: the basal ganglia and the cerebellum. They do not project 
directly to either the local circuit or lower motor neurons, but they influence movement by 
regulating the activity of upper motor neurons (Ferraye et al., 2010). 
The basal ganglia lie deep within the cerebral hemispheres and include: the caudate, putamen, 
globus pallidus (motor components), substantia nigra and the subthalamic nucleus. They 
make a subcortical loop and link most areas of the cortex with upper motor neurons in the 
primary motor and premotor cortex and in the brainstem. Here, the neurons respond in 
anticipation of and during movements, and their effects are required for the normal course of 
voluntary movements. When one of these structures is compromised, the patient cannot 
switch smoothly between initial commands and final commands of a movement. This is due 
to the absence of the supervisory control normally provided by the basal ganglia (Purves et 
al., 2001). 
 
3.1.1. The basal ganglia inputs 
The corpus striatum includes the caudate and putamen, and comprise the input zone of the 
basal ganglia. The destinations of the incoming axons from cortical, thalamic, and brainstem 
structures are the large dendritic trees of the medium spiny neurons. Then, the axons arising 
from these neurons converge on neurons in the globus pallidus and the substantia nigra pars 
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reticulata, which are the main sources of output from the basal ganglia complex (Purves et al., 
2001). 
The cerebral cortex is the source of the largest input to the basal ganglia. The heaviest 
projections are from association areas in the frontal and parietal lobes, but also from the 
temporal, insular, and cingulate cortices. They travel through the internal capsule and form 
the corticostriatal pathway (Crittenden and Graybiel, 2011). 
Caudate and putamen have functional differences. The caudate nucleus receives cortical 
projections from multimodal association cortices, and from motor areas in the frontal lobe that 
control eye movements. The putamen receives input from the primary and secondary somatic 
sensory cortices in the parietal lobe, the secondary visual cortices in the occipital and 
temporal lobes, the premotor and motor cortices in the frontal lobe, and the auditory 
association areas in the temporal lobe (Purves et al., 2001). 
The caudate, putamen, and ventral striatum receive cortical projections primarily from the 
association areas of the frontal, parietal, and temporal lobes. 
The corpus striatum is functionally subdivided according to its inputs. As an example, visual 
and somatic sensory cortical projections are topographically mapped within different regions 
of the putamen. 
The corticostriatal pathway consists of multiple parallel pathways serving different functions 
(observed when we analyze either the inputs or the outputs). 
Regions of different cortical areas concerned with the hand converge in specific rostrocaudal 
bands (functional units concerned with the movement of particular body parts) within the 
striatum; conversely, regions in the same cortical areas concerned with the leg converge in 
other striatal bands (Crittenden and Graybiel, 2011). 
A further indication of functional subdivision within the striatum is the spatial distribution of 
different types of medium spiny neurons, which occur in clusters of cells called “patches” or 
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“striosomes”, in a surrounding “matrix” of neurochemically distinct cells (limbic areas of the 
cortex project more heavily to the patches, whereas motor and somatic sensory areas project 
preferentially to the neurons in the matrix). 
Besides the nature of the signals from the cortex to the caudate and putamen are not 
understood, it is known that collateral axons of corticocortical, corticothalamic and 
corticospinal pathways originate glutamatergic synapses (excitatory) with medium spiny 
neurons. Note that the number of contacts established between a cortical axon and a medium 
spiny cell is very small, but the number of spiny neurons contacted by a single axon is 
incredibly large, which is named divergence (Purves et al., 2001). 
The medium spiny cells also receive noncortical inputs from interneurons, from the midline 
and intralaminar nuclei of thalamus, and from brainstem aminergic nuclei, which can 
modulate the effectiveness of cortical synaptic activation (cortical input). The aminergic 
inputs are dopaminergic and they originate in the substantia nigra pars compacta (Purves et 
al., 2001). 
As a result, the medium spiny neurons must simultaneously receive many excitatory inputs 
from cortical and nigral neurons to become active. Therefore these cells are usually silent. 
The firing of medium spiny neurons is associated with the occurrence of a movement. 
Neurons in the putamen tend to discharge in anticipation of body movements, whereas 
caudate neurons fire prior to eye movements. This is part of a movement selection process. It 
is known that the discharges of some striatal neurons vary according to the location in space 
of the target of a movement (Fahn and Jankovic, 2007). 
 
 
Gait disorders in Parkinson’s and Huntington’s diseases 
16 
 
 
Scheme 1: General pathway (adapted from Purves et al., 2001). 
 
3.1.2. The basal ganglia outputs 
The medium spiny neurons of the caudate and putamen originate inhibitory GABAergic 
projections that terminate in the internal division of the globus pallidus and in the substantia 
nigra pars reticulata. These are the major sources of the output from the basal ganglia. In fact, 
they have similar output functions, as substantia nigra pars reticulata is part of the globus 
pallidus, only separate from it by fibers of the internal capsule (Purves et al., 2001). 
Note that projections from the medium spiny neurons to the globus pallidus and substantia 
nigra converge onto pallidal and reticulata cells. On average, more than 100 medium spiny 
neurons innervate each pallidal cell (Fahn and Jankovic, 2007). 
The efferent neurons of the internal globus pallidus and substantia nigra pars reticulate give 
rise to the major pathways that link the basal ganglia with upper motor neurons in the cortex 
and in the brainstem. The pathway to the cortex arises in the internal globus pallidus, passes 
throw the ventral anterior and ventral lateral nuclei of the dorsal thalamus, and reaches the 
motor cortex. This loop originates in multiple cortical areas and terminates, after relays in the 
Cerebral cortex 
Corpus striatum            
(putamen and caudate) 
Globus pallidus          
Substantia nigra pars reticulata 
Thalamus (VA/VL complex) 
Superior colliculus 
+ 
- 
+ 
- 
- 
+ 
Substancia nigra 
pars compacta 
Subthalamic 
nucleus 
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basal ganglia and thalamus, back in the motor and premotor areas of the frontal lobe. On the 
other hand, the neurons from substantia nigra pars reticulata synapse in the superior colliculus 
(monosynaptic projections), commanding eye movements. However, this difference between 
the globus pallidus and substantia nigra pars reticulata is not absolute. 
The main output of the basal ganglia is inhibitory, since the efferent cells are GABAergic 
(like the projections from the medium spiny neurons). However, in contrast to those quiescent 
cells, these neurons have high levels of spontaneous activity that tend to prevent unwanted 
movements by tonically inhibiting cells in the superior colliculus and thalamus (Purves et al., 
2001). 
The net effect of the excitatory inputs from the cortex to the striatum is to inhibit the tonically 
active inhibitory cells of the globus pallidus and substantia nigra pars reticulata. 
What normally happens in the absence of body movements is that the globus pallidus neurons 
provide tonic inhibition to the relay cells in the VL and VA nuclei of the thalamus, as the 
cerebral cortex, the substantia nigra pars compacta and the striatum are silent (Boonstra et al., 
2008). 
What normally happens in the presence of body movements is that the neurons from cerebral 
cortex and substantia nigra pars compacta fire, originating the inhibition of the pallidal cells 
by activity of the medium spiny neurons, and consequently the desinhibition of the thalamic 
neurons. As a result, they can relay signals from other sources to the upper motor neurons in 
the cortex, and from there to local circuit and lower motor neurons that initiate movements 
(Fahn and Jankovic, 2007). 
An abnormal increase in the tonic inhibition as a consequence of basal ganglia dysfunction 
leads to few excitability of the upper motor neurons, and thus to the hypokinetic movement 
disorders such as Parkinson’s disease (PD). 
Gait disorders in Parkinson’s and Huntington’s diseases 
18 
 
An abnormal reduction in the tonic inhibition as a consequence of basal ganglia dysfunction 
(because of the indirect pathway, explained later) leads to excessive excitability of the upper 
motor neurons, and thus to the involuntary movement and hyperkinetic syndromes that are 
characteristic of basal ganglia disorders such as Huntington’s disease (HD) (Fahn and 
Jankovic, 2007). 
 
3.1.3. The basal ganglia circuits 
The projections from the striatum to the globus pallidus internal and substantia nigra pars 
reticulata form in part a “direct pathway”, which serve to release the upper motor neurons 
from tonic inhibition, and an “indirect pathway”, that increases the level of tonic inhibition on 
the upper motor neurons (Cowie et al., 2010). 
In this last pathway, the striatum projects to the external segment of the globus pallidus, 
which sends projections both to the internal segment of the globus pallidus and to the 
subthalamic nucleus of the ventral thalamus. This one, with excitatory neurons, projects back 
to the globus pallidus internal and to the substantia nigra pars reticulata, and then out of the 
basal ganglia, as described. The indirect pathway serves to modulate the disinhibitory actions 
of the direct pathway (Fahn and Jankovic, 2007). 
What normally happens when the indirect pathway is activated by signals from the cortex is 
that the striatum inhibits the tonically active GABAergic neurons of the globus pallidus 
external, making the subthalamic neurons more active and thus increasing the inhibitory 
outflow of the basal ganglia. The direct and the indirect pathways are an example of interplay 
between excitation and inhibition, used to achieve control (Purves et al., 2001). 
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Scheme 2: Indirect and direct basal ganglia pathways (adapted from Purves et al., 2001). 
 
3.2. Verifying disorders in the circuits and pathways 
What happens if the fine control of the subthalamic nucleus is destructed is that a source of 
excitatory input to the globus pallidus internal and reticulata is removed, reducing the 
inhibitory outflow of the basal ganglia to the upper motor neurons. That result in a syndrome 
called hemiballismus, characterized by violent and involuntary movements of the limbs 
(Purves et al., 2001). 
The dopaminergic cells in the substantia nigra pars compacta modulate the output of the 
corpus striatum. This one projects directly to compacta, which sends dopaminergic 
projections back to the spiny neurons. These influences are complex, because there are: 
excitatory inputs that project to the internal globus pallidus (D1 type dopaminergic receptors) 
– direct pathway – and inhibitory inputs that project to the external globus pallidus (D2 type 
receptors) – indirect pathway. However, these differences between the influences of the 
nigrostriatal axons produce the same effect: a decrease in the inhibitory outflow of the basal 
ganglia and thus an increase in the excitability of the upper motor neurons (Cowie et al., 
2010). 
Frontal cortex 
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Disorders in this second internal circuit explain many syndromes. PD, for example, is caused 
by the loss of nigrostriatal dopaminergic neurons. So, when the compacta cells are destroyed, 
the inhibitory outflow of the basal ganglia is abnormally high, and activation of upper motor 
neurons is less likely to occur. Indeed, PD is a hypokinetic movement disorder, where any 
movement is difficult to initiate and, once initiated, is difficult to terminate. Also, the 
resulting increase in tonic inhibition in the superior colliculus causes reduction in frequency 
and amplitude of saccades (Purves et al., 2001). 
In the same way, understanding the indirect pathway helps to explain the motor abnormalities 
seen in HD. In this disease, medium spiny neurons that project to the external globus pallidus 
degenerate. In the absence of their normal inhibitory input, the external globus pallidus cells 
become abnormally active, which reduce in turn the excitatory output of the subthalamic 
nucleus to the internal globus pallidus. The inhibitory outflow of the basal ganglia is, 
eventually, reduced. Consequently, upper motor neurons can be activated by inappropriate 
signals, resulting in the ballistic and choreic movements that characterize HD (Fahn and 
Jankovic, 2007). 
Other non-motor systems can be also influenced by the basal ganglia, with similarly important 
clinical implications (oculomotor loop, prefrontal loop, limbic loop). 
The pathological changes in neurological diseases can provide insights about the function of 
the basal ganglia. For instance, the substantia nigra is largely absent in the region above the 
cerebral peduncles in patients with PD. Another example is the size of the caudate and 
putamen (the striatum), which is dramatically reduced in patients with HD (Purves et al., 
2001). 
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3.3. Parkinson’s disease 
 
3.3.1. Definition and general features 
PD is the second most common degenerative disease of the nervous system (Alzheimer’s 
disease is the leader). 
It was described by James Parkinson in 1817 and it is characterized by bradykinesia (slowness 
of movement) and hypokinesia, resting tremor, altered gait, rigidity of the extremities and 
neck (muscular rigidity), postural instability, minimal facial expressions, together with 
autonomic dysfunctions. What’s more, gait is characterized by short steps, stooped posture, 
and a deficit of associated movements like arm swinging. Sometimes this is associated with 
dementia. Fifteen to twenty years after the onset, the slowly progressive disease can culminate 
in death (Purves et al., 2001). 
The motor defects are the result of the progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta. The cause (etiology and pathogenesis) of the deterioration of 
these dopaminergic neurons is largely unknown, but genetic investigations are taking part. 
The majority of cases of PD are sporadic; nevertheless there are some susceptibility genes that 
confer increased risk of acquiring the disease (less than 10 % of all cases) (Purves et al., 
2001). Mutations of three distinct genes (α-synuclein, Parkin and DJ-1) have been found in 
rare forms of PD. Identification of these genes can open more ways of elucidating the 
pathogenesis and testing therapies (Fahn and Jankovic, 2007). 
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3.4. Huntington’s disease 
 
3.4.1. Definition and general features 
HD was described by George Huntington in 1872 and it is characterized by the gradual onset 
of defects in behavior, cognition and movement, beginning in the fourth and fifth decades of 
life (occasionally in childhood or adolescence - Juvenile Huntington’s disease), lasting ten to 
twenty years and resulting in death (Roos, 2010). 
HD has an autosomal dominant pattern, and usually presents as an alteration in mood (e.g. 
depression) or a change in personality like increased irritability, suspiciousness and 
impulsive/eccentric behavior (Purves et al., 2001). Defects of memory and attention can also 
occur. However, the most remarkable features are: rapid, jerky movements with no clear 
purpose, which can be confined to a finger or can involve a whole extremity, the facial 
musculature or even the vocal apparatus, named chorea. They are involuntary, but the patient 
incorporates them into apparently deliberate actions, in order to hide the problem. There is no 
weakness, ataxia or sensory deficit. In juveniles, there is rigidity, seizures, augmented 
dementia and a faster progressive course (Roos, 2010). 
A profound but selective atrophy of the striatum, with some associated degeneration of the 
frontal and temporal cortices are present. These can explain the disorders of movement, 
cognition and behavior, and the sparing of other neurological functions. 
In 1983, the HD mutant gene was mapped to the short arm of chromosome 4 (4p16.3), by 
DNA polymorphisms. The positional cloning helped to identify the HD gene, HTT gene. Its 
mutation is an unstable triplet repeat, which passes from 15-34 repeats (in normal individuals) 
to 36-66+ in HD patients. The repeats consist of a DNA segment (CAG) that codes for the 
aminoacid glutamine and is present within the coding region of the gene. The longer the CAG 
Gait disorders in Parkinson’s and Huntington’s diseases 
23 
 
repeats, the earlier the onset of the disease. In cases of Juvenile Huntington’s disease the 
repeat often exceeds 55 (Purves et al., 2001; Roos, 2010). 
These increased numbers of glutamines alter protein folding, which somehow triggers a 
cascade of molecular events culminating in dysfunction and neuronal death. 
Unexpectedly, huntingtin is also expressed in regions of the brain that are not affected in HD 
and in many other organs outside the nervous system. Why the mutant huntingtin only injures 
striatal neurons is still unclear (Purves et al., 2001). 
 
3.5. Features of gait disorders in Parkinson’s disease 
Altered gait (walking pattern) is one of the features of the PD. Stride length, gait variability 
and fractal-like scaling of gait are all impaired in PD (Hausdorff, 2009). 
About 20% of people over the age of 80 have Parkinsonism associated gait disturbances. The 
major motor disturbances in PD have been yet referred. 
 
3.5.1. Classification 
The gait disturbances in PD can be divided into two types: continuous and episodic. The last 
ones occur occasionally, without an explanation, and include festination, start hesitation, and 
freezing of gait (FOG) - in patients with advanced PD. On the other hand, the first ones 
appear to be consistent and persist all the time. They include: shortened stride length, 
augmented gait variability and diminished fractal scaling. Certain episodic symptoms are 
associated with other continuous symptoms, for example patients with FOG have increased 
gait variability. Although both types of gait disturbances are a result of basal ganglia 
dysfunction, the specific mechanisms responsible for the episodic and continuous gait 
disturbances are independent. However, both contribute to the risk of falls in PD, which are 
the most significant consequences of a disturbed gait in PD (Boonstra et al., 2008). 
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As the disease progresses, gait impairment and falls become one of the principal complaints 
among PD patients.  In a study, 43% of the PD patients reported at least one fall in 12 months 
(Hausdorff, 2009). Almost a double of what is seen in healthy adults. Fall rates were even 
higher in studies that also included “near falls” (missteps and loss of balance). And we cannot 
forget all the negative consequences of falls. 
 
3.5.2. Continuous gait disturbances investigation 
Continuous gait disturbances that can be seen using visual observation are: reduced gait speed 
with decreased arm swing, longer double limb support, and impaired postural control. These 
may be explained by the reduction and shortening of stride length (Chee et al., 2009). 
There is also gait disturbances, like increased gait variability, which only becomes apparent 
when gait is evaluated quantitatively with gait analysis systems, such as: increased left-right 
asymmetry, diminished left-right bilateral coordination, and higher stride-to-stride variability. 
Those characteristics can be seen in all patients with PD. 
Gait variability (unsteadiness or inconsistency and arrhythmicity of stepping) is closely 
associated with risk of falls and postural instability. However it is independent of gait speed. 
When a long time scale is used, some variability is a sign of health; but in the short time scale, 
increased variability is a sign of diminished control. The last one can be decreased by 
therapeutic interventions (levodopa), although it remains always increased in fallers compared 
to nonfallers. That was confirmed by the findings of Hausdorff (2009) whose results 
demonstrate that levodopa has a benefic effect on increased gait variability and that dopamine 
circuits contribute to control gait variability. However, PD patients who fall can regulate this 
variability better than the others, which probably mean that they have increased impairment in 
those circuits and respond better to therapy. 
Gait disorders in Parkinson’s and Huntington’s diseases 
25 
 
Conversely, fall frequency and gait variability are not very related to tremor, rigidity or 
bradykinesia, in the OFF state (features that arise more than 12h after the last intake of anti-
Parkinsonian medication, when the drug effect is minimal) (Moore et al., 2007). 
About the pathophysiology of bradykinesia, the dopaminergic projection to the striatum 
provides a signal for implicit “motor motivation”. Patients with PD have a higher probability 
of moving slowly because of a specific distortion of speed selection mechanisms: movements 
with lower energy expenditure are favored although a range of normal movements is 
available. It means that movement speed is determined not only by the speed-accuracy 
exchange (that can be normal in PD patients) but also by an implicit value assigned to 
movement energy cost, which is manifested as response intensity: movement vigor (that is 
altered in PD patients). Thus, dopamine from the substantia nigra to the striatum carries also a 
signal for “motor motivation” (Mazzoni et al., 2007). 
Average stride length, gait variability, and the fractal-like property of gait in PD (continuous 
gait disturbances) are all related. 
 
3.5.2.1. The fractal-like scaling 
How gait changes over time, from one stride to the next within a given walk is explained 
bellow. In healthy adults, gait is relatively unvarying. Still, closer examination reveals small 
stride-to-stride changes in the gait pattern. A good example is that the stride time (stride 
interval: time from initial contact of one foot to subsequent contact of the same foot) varies 
about its mean (Cowie et al., 2010). For a long time, it was assumed that there is no meaning 
in these changes, but recently some studies have demonstrated the opposite: each stride time 
is related to stride times ten and hundreds of strides later. Stride-to-stride fluctuations reflect 
long-range correlations in the stride time and suggest a wider control (even during slow 
walking and during running). This is the fractal-like property of gait, which can be quantified 
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using a modified random walk analysis (detrended fluctuation analysis – DFA) (Moore et al., 
2007). 
It signifies the presence of long-term memory in the locomotor control system. This scaling 
reduces the risk of perturbations, because as there is a range of different measures to stride 
time, it makes more difficult to originate problems in the walking pattern (variety, here, 
means stability). Thus, a fractal-like gait may be more flexible and adaptable (Hausdorff, 
2009). 
The fractal dynamics of the stride interval are largely independent of speed and intrinsic to the 
locomotor system. What is more, different aspects of stride dynamics mature at different ages; 
the fractal scaling index is lower in the healthy older adults compared to young adults 
(Hausdorff, 2009) and even lower in PD patients. The fractal-behavior promotes adaptability. 
The long-range correlations in gait are related to CNS mechanisms (as it will be described in 
Treadmill walking and dual tasking and Methylphenidate sections). The fractal-like scaling 
has higher-level origins (Cowie et al., 2010). 
 
3.5.3. Gait dynamics 
There have been some efforts aimed at measuring the gait rhythm, the timing of the gait cycle 
(stride time, as described above), the swing time (time when one foot is in the air), and stride 
length, which seemed to be a much more difficult task (Hausdorff, 2009). 
To quantify how the dynamics fluctuate over time during walk, it is usual to apply DFA to 
each subject’s sequence of stride times (Moore et al., 2007). 
Many healthy physiologic systems have fractal scaling indices of around 0.8 – 1.0 and values 
closer to 0.5 reflect a deviation from the healthy state. Previous work has shown that the 
fractal scaling index provides a measure of subtle changes in gait dynamics, which can 
separate healthy young from healthy older adults (Hausdorff, 2009). 
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3.5.4. Changes in the fractal scaling in Parkinson’s disease 
Among patients with PD, the stride-to-stride fluctuations in gait become more random, and 
the DFA scaling exponent becomes close to 0.5 (the value for white noise, an absence of 
long-range correlations) (Moore et al., 2007). 
The breakdown of the long-range correlations could be interpreted in different ways; one of 
them is that among patients with PD, gait loses its automaticity and fluidity. Each stride starts 
a new process, unrelated to the previous stride, and the memory of the locomotor control 
system is not long term and fractal-like anymore, but instead it becomes close to zero. Some 
statistical models have shown that many of the observed changes can be explained by the 
combination of neighboring neural networks and a loss of neurons (Hausdorff, 2009). 
 
3.5.5. Gait features in mild Parkinson’s disease 
To better understand the pathophysiological mechanisms that influence gait in PD, it is 
helpful to identify the early alterations, in patients not yet treated with anti-Parkinsonian 
medications (de novo PD). However, only a few quantitative investigations have already 
taken part (Chee et al., 2009). 
PD alters the generation and regulations of a consistent gait rhythm, even early in the course 
of the disease, when observed alterations are not the result of any pharmacologic treatment 
and are largely confined to dopamine depletion in the nigro-striatal pathway. 
Patients with early stage PD walk more slowly, with reduced swing times, increased left/right 
swing asymmetry and marked inconsistencies in the timing of gait (increased variability 
compared to controls). On the other hand, the fractal scaling exponent is not very different 
from that seen in healthy people. In de novo PD an altered gait pattern is already present, even 
though without dramatic changes (fairly intact gait speed). They have reduced stride length, 
increased gait variability and asymmetry in timing (Snijders et al., 2010). 
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So, in the mild PD the behavior of the stride-to-stride fluctuations (fractal-like scaling) is 
almost intact, suggesting that this feature only becomes impaired later in the disease process. 
It is still unknown if there is any compensatory mechanisms or if the basal ganglia are not 
sufficiently damaged, in this early stage of the disease. 
The different gait features are usually associated. Stride length is a fundamental property of 
gait.  Gait speed and stride length are strongly associated. Gait variability is moderately 
associated with them. Furthermore, the fractal scaling index is not significantly correlated 
with variability, gait speed, or stride length (Hausdorff, 2009). 
 
3.5.6. Effects of new approaches 
 
3.5.6.1. Rhythmic Auditory Stimulation 
Rhythmic auditory stimulation (RAS) can improve many spatiotemporal features of gait in 
patients with PD by providing an external clock that sets the pace and replaces the impaired 
internal rhythmicity in PD. It is a kind of physiotherapy (Boonstra et al., 2008). 
Using RAS, administered in the form of a metronome, improves: gait speed, stride length, and 
double support time, both in the ON and OFF states (after taking anti-Parkinsonian 
medication, when symptoms are minimal, and more than 12h after the last intake of anti-
Parkinsonian medication, when the drug effect is minimal, correspondingly). These effects 
may persist even when walking without stimulation (Moore et al., 2007). 
However, when RAS is set to the subject’s usual-walking rate, variability doesn’t improve 
significantly. But, when the RAS is set 10% higher than usual-walking pace, variability 
considerably decreases. Moreover, 15 min after walking with RAS at 10% higher, stride 
length and variability are still notably better than the baseline values. 
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Conversely, the fractal scaling index is unresponsive to RAS, and among healthy subjects 
RAS has no significant effects on stride length, variability or the DFA scaling exponent 
(Hausdorff, 2009). 
Recent preliminary results suggest that auditory stimulation which includes small fluctuations 
about the mean, and not a simple constant pacing, may have more beneficial effects on the 
gait of patients with PD, compared to purely RAS (similarly to the constant pacing of a 
treadmill). However, treatment of movement disorders has not yet adapted this concept 
(Sollinger et al., 2010). 
 
3.5.6.2. Treadmill walking and dual tasking 
Using a treadmill has potential to improve Parkinsonian gait. The treadmill can be used as an 
external cue to help restore and augment the impaired “pacemaker”. It is proved that the 
treadmill reduces stride time variability and swing time variability, even in PD and healthy 
subjects, but the fractal scaling index does not change. Nevertheless, walking with a walking 
aid on level ground improves gait speed, but there is no effect on the fractal scaling or 
variability (Nilsson and Hagell, 2009). 
So, during treadmill walking, PD subjects are able to walk with a less variable and more 
stable gait. Therefore, treadmill can be used as a pacemaker. 
Gait speed and variability have independent natures. 
Dual tasking (the performance of another task while walking) can alter the gait pattern. 
Healthy adults usually reduce the gait speed. Older adults reduce the gait speed and the 
duration of swing, and increase the support time, while gait variability is not affected. PD 
patients reduce the gait speed and the swing time, increase gait variability and decrease gait 
bilateral coordination (Boonstra et al., 2008). 
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Normally, as the degree of cognitive loading worsens, so do gait variability and the fractal 
scaling index in PD, compared to usual walking. In contrast, gait speed decreases similarly 
even in healthy and in PD subjects. The cognitive domain has an extremely important role in 
the maintenance of a steady gait (Hausdorff, 2009). 
 
3.5.6.3. Methylphenidate 
Methylphenidate (MPH) is a central nervous system stimulant derived from amphetamine that 
works as a potent inhibitor of catecholamine reuptake. It is used to treat attention deficits in 
children and adults with hyperactivity disorder. 
Since dopamine reuptake plays an important role in the regulation of dopamine in the 
synapse, and the hypodopaminergic state is at the basis of the PD, MPH may improve motor 
function in PD (Boonstra et al., 2008). 
It is known that PD patients have declined attention abilities and the cognitive domain has an 
extremely important role in the maintenance of a steady gait. That’s why MPH can improve 
gait and reduce fall risk in PD subjects. 
In response to MPH, cognitive function (attention and executive function) significantly 
improves, while memory and visual-spatial performance do not change. Gait speed, stride 
time variability and the fractal scaling index also notably improve. 
Increasing attention can positively impact gait speed, gait variability, and the fractal scaling 
index in patients with PD, also other mechanisms may intervene here (Hausdorff, 2009). 
Therapeutic interventions that improve gait properties have a profound, positive impact on 
Parkinsonian gait, fall risk, and the health-related quality of life of these patients. It is part of 
PD pharmacotherapy (Boonstra et al., 2008). 
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3.5.7. Episodic gait disturbances investigation 
Freezing of gait (FOG) has been identified as one of the main contributors to gait disturbances 
in PD, and it affects more than one-third of the patients mainly in the advanced stage of the 
disease (Moore et al., 2007). It is known that reduced step length and the step to step 
reduction in amplitude may lead to the occurrence of FOG. The number of FOG episodes 
increase in patients with 50% of the normal stride length and further increase in patients with 
25% of the normal stride length, compared to other conditions (patients without FOG). When 
the step length is artificially reduced (increasing step length variability), the same effects are 
observed as when there is an automatic reduction in step length during normal walking in a 
variable environment requiring different amounts of conscious attention (Chee et al.,  2009). 
FOG is a paroxysmal phenomenon commonly seen in advanced PD and can be defined as an 
unintentional and temporary phenomenon where the feet fail to progress (Cowie et al., 2010). 
Freezing episodes are transient, generally lasting for a few seconds, and tend to increase in 
frequency as the disease progresses. An episode of freezing can be considered to have ended 
when the patient takes at least two steps at or near their normal step length (Boonstra et al., 
2008). 
FOG that arises after taking anti-Parkinsonian medication, when symptoms are minimal, is 
named FOG in the ON state. FOG that arises more than 12h after the last intake of anti-
Parkinsonian medication, when the drug effect is minimal, is named FOG in the OFF state 
(Moore et al., 2007). 
Environmental constraints requiring a change in the gait speed, pattern or direction, such as an 
obstacle, turning, walking in confined spaces or on reaching a destination will often trigger a 
freezing episode (Snijders et al., 2010). They can also occur spontaneously when walking in 
an open space, in the later stages of PD. FOG is also influenced by cognitive factors, such as 
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stress, anxiety and attention (dual tasks). The main common cause is the reduction in step 
length. 
FOG is usually evoked in crowded and confined spaces as well as when having limited time, 
like when crossing a street. It is one of the most distressing symptoms in PD, and it is 
associated with longer disease duration, more advanced disease stage, falls, dyskinesias, and 
decreased mobility (Nilsson and Hagell, 2009). Stride-to-stride variability further increases in 
patients with PD who experience FOG in the OFF state. 
Festination is a less severe gait disorder than akinetic FOG, and both forms are less severe 
compared to a disordered gait with a need for external help to continue walking (Ziegler et al., 
2010). 
Iansek et al. (2006) suggested that FOG during walking was possibly due to the presence of 
the sequence effect (gradual step to step reduction) in combination with an overall reduced 
step length which, if small enough, would eventually lead to freezing. However, that 
hypothesis was based on the duality of basal ganglia function and malfunction in PD in the 
elaboration of automatic movement in conjunction with the supplementary motor area. The 
basal ganglia maintains cortically selected motor set in the supplementary motor area and 
provides internal cues to that motor area in order to enable each sub movement to be correctly 
linked together. Contrary to hypokinesia, the sequence effect does not respond to medication 
or attention strategies. It does disappear with the use of external cues: goal directed behavior 
and gait. It also suggested that the dual causation of hypokinesia and shortening of steps lead 
to the occurrence of FOG during walking, on the basis that the sequence effect was present 
before the onset of freezing. 
Five subtypes of freezing have been identified: start hesitation at initiation of walking, 
freezing on turning, freezing in restricted areas, destination freezing, and open space 
hesitation in the absence of stimuli likely to result in FOG (Chee et al., 2009). 
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Other possible explanations for FOG include the dysfunctional execution of internally 
generated motor sequences in gait (asymmetric gait and timing disorder), and spatial vision 
processing errors (Sollinger et al., 2010). People who experience FOG commonly use 
“rescue” techniques such as imagery or inverted walking sticks; one theory is that this use of 
visual information bypasses the basal ganglia and a normal step length is produced. Gait 
vastly improves when visual cues are set for a normal step length (Chee et al., 2009), 
exemplifying that there is a perceptual cause for this motor impairment (Almeida and Lebold, 
2010). It appears that freezing is related to dopamine deficiency, as levodopa therapy does 
have some effect on alleviating it, specifically by decreasing the frequency and duration of 
freezing episodes. 
Factors which increase preferred step length may equally eliminate FOG and these include 
focused attention, attentional strategies, medication and visual cues (goal directed behavior). 
Only the latter, however, eliminate the sequence effect. 
Rehabilitative techniques should focus on assisting PD patients to concentrate on maintaining 
step length during walking episodes to prevent gait difficulties (Chee et al., 2009). 
 
3.5.8. Axial mobility deficits in Parkinson’s disease 
Patients with PD often have difficulty turning around, not only while lying in bed, but also 
while standing upright. Turning problems may result from inability to adequately maintain an 
interlimb coordination, and also from axial rigidity and loss of intersegmental flexibility 
(Boonstra et al., 2008). 
Another factor that may contribute to postural instability is the osthostatic myoclonus or 
tremor, which improves on levodopa or clonazepam, correspondingly. In contrast to tremor, 
axial deficits were related to increases in ventricular volume (seen using MRI). Asymmetries 
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in gait are also a symptom of early stage PD, present even though stride-to-stride variability is 
normal, in the early stages. 
Walking and standing are not purely automatic tasks, regulated only by subcortical control 
mechanisms. Gait is a complex “higher-order” form of motor behavior, with varied influences 
of mental processes, which become evident when PD patients are unable to deal with multiple 
tasks simultaneously (Iansek et al., 2006) 
Postural instability is not only a result of disturbed motor programming of postural 
corrections within the basal ganglia (efferent deficit) but also a result of central proprioceptive 
disturbances (afferent deficit), seen also in arm movements. 
There is some balance correcting strategies to prevent patients from falling, like stretching out 
the arms and taking compensatory steps. However, PD patients have difficulties initiating a 
compensatory step, as that failure may be due to impairment of anticipatory postural 
adjustments. External help or visual inputs (e.g. a visual target) can ameliorate compensatory 
stepping, but the impossibility to see their own legs deteriorate it (Chee et al., 2009). 
 
3.6. Features of gait disorders in Huntington’s disease 
HD is a phenotypically heterogeneous disease characterized by chorea, dystonia, 
bradykinesia, cognitive decline and psychiatric comorbidities. Balance, gait impairments, and 
falls, are common manifestations of the disease (Goldberg et al., 2010) 
The diagnosis of HD is based on the presence of an extrapyramidal movement disorder in the 
context of a positive family history of HD (Rao et al., 2008). Impairment of voluntary 
movements and gait are present through the course of the disease and worsen with disease 
progression, in relation with marked loss of function. 
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In HD patients, gait is characterized by a timing disorder with marked intraindividual 
variability in temporal gait parameters (caused by the presence of both hyperkinetic and 
hypokinetic features) (Delval et al., 2008). 
Walking is often described as “drunk” or “cerebellar ataxia”-like. Distinguishing between 
choreatic and ataxic walking is very difficult. Pyramidal signs (Babinski sign) are present 
incidentally (Roos, 2010). 
Gait, bradykinesia and dynamic balance impairments begin in the presymptomatic stage of 
HD and continue to worsen in the symptomatic stages. 
Motor dysfunction including gait and balance disturbances, chorea and dystonia, 
Parkinsonism, and other signs and symptoms (oculomotor abnormalities, dysarthria, and 
dysphagia), contribute substantially to the functional burden of the disorder (Feigin, 2011). 
 
3.6.1. Gait impairments in Huntington’s disease 
Important gait impairments in symptomatic HD subjects include: decreased gait velocity, 
decreased stride length, decreased cadence, disordered temporal control of gait, and greater 
variability in spatial and temporal measures compared with healthy subjects (Delval et al., 
2006). Balance impairment has been demonstrated as a compensatory increase in base of 
support during walking (Paulsen et al., 2006). Gait bradykinesia is a result of decreased stride 
length and decreased cadence; increased variability in temporal control is caused by inability 
to modulate internal cues or integrate sensory stimuli for movements (Delval et al., 2006). 
Increased stride-to-stride variability may reflect defective neural gait machinery, plus a 
contribution from excessive choreatic movements (Grimbergen et al., 2008). 
In Rao et al. (2008) study, impairments in stride length (decreased amplitude and increased 
variability) began in the presymptomatic stage of HD whereas impairments in cadence were 
only seen in the symptomatic stages of HD. Gait velocity is modulated through control of 
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stride length and cadence. Also, impairment in double support time began in the 
presymptomatic stages of HD, whereas increases in base of support were only seen in 
symptomatic HD subjects. Gait outcome measures may serve as sensitive behavioral markers, 
particularly in the early stages of HD, and quantitative gait assessment was very sensitive in 
differentiating between subjects with and without the HD mutation. 
 
 
Graphic 1. 
 
 
Graphic 2. 
Gait disorders in Parkinson’s and Huntington’s diseases 
37 
 
 
Graphic 3. 
Graphics 1, 2 and 3: Show comparison of stride length, stride length coefficient of variation, 
and percent time in double support for controls, presymptomatic mutation carriers (PMC), 
symptomatic HD (SHD) stage I, SHD stage II and SHD stage III subjects. The horizontal 
lines represent the cutoff value at which sensitivity and specificity were optimal. (Rao et al., 
2008) 
Also presymptomatic HD subjects have significant gait impairments such as gait bradykinesia 
and dynamic balance impairment, consistent with reports of bradykinesia in hand and eye 
movements.  In addition, they demonstrate greater variability in gait (compared with non-HD 
patients), as well as in arm and hand movements. Gait impairments begin very early in HD, 
before onset of clinically observable symptoms (Paulsen et al., 2006). 
The cause of gait bradykinesia in symptomatic HD is unclear: while some studies suggest that 
bradykinesia may arise due to reduced stride length and cadence (Rao et al., 2008), others 
indicate that bradykinesia may arise due to a problem with cadence regulation (Delval et al., 
2007). 
Motor impairments may arise due to pathology in the thalamocortical projections from the 
basal ganglia, as cellular degeneration in the basal ganglia has been reported well before onset 
of motor symptoms. Structural MRI scans have shown that basal ganglia volume is decreased 
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in presymptomatic HD compared with non-HD patients and continues to decrease in the 
symptomatic stages. Decreased amplitude of somatosensory evoked potencials in the 
thalamocortical pathway may be related to cellular degeneration, indicating a disorder in the 
feedback sensory loop between basal ganglia and frontal motor areas (Paulsen et al., 2006). 
Gait impairments begin well before clinically observable symptoms, and gait measures may 
be sensitive markers for detecting subtle changes. 
 
3.6.2. The role of external cueing 
A reduction in cadence, walking speed, and stride length, as well as an increase in stride-to-
stride variability, are some of the features observed. Executive deficits are also of major 
importance, as concurrent performance of motor and cognitive tasks can have marked effects 
on gait in PD patients but also in HD patients. It has been suggested that external auditory and 
visual cues may be useful for maintaining gait performance by improving attentional 
resources, directing attention to the task of walking, as rhythmic cues may act by 
compensating for defective internal cue generation by the basal ganglia in PD, for instance, 
because they can synchronize their footsteps with a metronome. However, HD patients fail to 
achieve the cadence set by the metronome, which can be related to the attentional deficits that 
are present in HD, worse than in PD. Moreover, HD patients present an important inability to 
suppress interfering information (Delval et al., 2008). 
The fact that a metronome (which can replace the internal cueing provided by the basal 
ganglia and by the internal pallidum) does not improve gait points to the hypothesis that 
different motor circuits can be altered in HD: the pallidothalamic excitation leading to 
hyperkinesia can interfere in the early stages of the disease, explaning the gait instability. 
Both motor and cognitive circuits are involved in HD patients’ failure to synchronize gait 
with a metronome (Delval et al., 2008). 
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3.6.3. Risk factors for falls in Huntington’s disease 
Little is known about the epidemiology, circumstances and consequences of falls, as well as 
about the pathophysiology underlying falls in HD. Firstly, motor symptoms such as chorea or 
bradykinesia (leading to inappropriate execution of corrective steps or protective arm 
movements and reduced step height) may disturb balance and gait, contributing to falls and 
increasing the risk of tripping. Secondly, balance may be compromised by abnormal postural 
reflexes, leading to inadequate responses (like balance correcting, in leg muscles) to external 
perturbations. Thirdly, disturbances in behavior and cognition (like aggression and 
inattention, respectively) can underlie falls in HD. Factors such as use of sedative medication 
and alcohol intake can also originate falls (Grimbergen et al., 2008). 
In Grimbergen et al., 2008, study quantitative analyses revealed abnormalities of gait and 
balance that were more pronounced in HD patients with falls compared to patients without 
falls, and no serious injuries were reported. In addition, only few patients were afraid of 
falling, which is the opposite of the PD patients. This study also indicate that recklessness do 
not contribute much to falls and injuries. Balance deficits in HD are not that prominent and 
may progress slowly, allowing for compensatory strategies to develop. 
Factors that may contribute to the pathophysiology underlying falls in HD are: excessive 
choreatic trunk movements that lead to unstable walking (increased postural sway); 
bradykinesia (reduced step height and walking speed); balance impairment, but with a minor 
role; cognitive decline (as observed also in Alzheimer’s disease and PD), associated with 
balance disorder; indeed, the majority of falls in HD occur under so-called “multiple task” 
circumstances (Camicioli et al., 2006; Pluijm et al., 2006; Pickering et al., 2007; Voermans et 
al., 2007). 
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3.6.4. Compensatory techniques 
Compensatory rapid stepping to maintain equilibrium in older adults is established, but little 
is known about the role of stepping response times (SRTs) in balance control in people with 
HD. 
HD patients exhibit slower SRTs, lower balance confidence, and poorer dynamic balance, 
mobility and motor performance than non-HD patients. SRT appears to be sensitive to 
detecting real changes in people with HD, and is an objective marker of disease progression 
(Goldberg et al., 2010). 
While walking, humans move the body’s center of mass over the base of support to restore 
equilibrium, and the execution of a compensatory step may be required to rapidly alter the 
base of support to restore stability during challenges to equilibrium in daily activities (Rao, 
Louis and Marder, 2009). 
HD patients have: slower SRT, slowed gait, prolonged reaction time, slowed movement time 
of the upper extremity, and longer reaction time and reduction in speed of the first step of 
ambulation, findings that are consistent with bradykinesia as an integral feature of the disease 
phenotype (Goldberg et al., 2010). 
Deficits in SRT are associated with impairments on clinical measures of balance, mobility, 
and motor performance. It correlates with gait-related predictors of institutionalization. 
SRT may be useful in assessing disease progression, as well as the efficacy of pharmacologic 
(neuroprotective agents) and rehabilitative interventions. Only SRT changes exceeding 241.8 
ms should be considered to reflect real change in people with HD (Goldberg et al., 2010). 
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3.7. Assessments: scales 
The clinical assessment of the symptoms and signs of PD and HD is important for patient, 
family and care-givers. To follow the patient systematically, mainly for research purposes, 
several scales have been developed. 
Patient-reported assessments (self-evaluation) of FOG in PD, such as FOG Questionnaire 
(FOGQ), are needed because FOG is difficult to assess objectively. Therefore, Giladi et al., 
2000, developed the FOGQ, a clinician administered patient-reported rating scale. FOGQ 
scores are correlated with PD duration, the Timed Up and Go test (see below), fear of falling, 
dyskinesia and motor fluctuations, which is not surprising as they are associated with more 
severe PD and so with FOG. Fallers have higher FOGQ scores than non-fallers (Nilsson and 
Hagell, 2009). 
Among the approaches to achieve a standardized measurement of FOG is the “old” United 
Parkinson’s Disease Rating Scale (UPDRS), which assesses the severity dimension. It does 
not differentiate the symptom from the cause, and records frequency and consequential falls 
on one scale. It also does not evaluate FOG in dual-task situations, but only in the context of 
the Parkinsonian movement disorder (Ziegler et al., 2010). The motor part of the UPDRS 
emphasizes the classic trias of Parkinsonian symptoms, such as tremor, rigidity, and 
bradykinesia, and has not been designed to include symptoms of movement initiation, such as 
freezing (Ziegler et al., 2010). 
The 14-item Parkinson-Activity-Scale (PAS) assesses general mobility, and includes six 
questions that are related to FOG during starts or turns, in the context of the Parkinsonian 
movement disorder (Ziegler et al., 2010). 
To ensure valid and reliable measurement of FOG, a combined methodology with tests of 
complex gait together with a FOGQ has been recommended, named FOG score (Ziegler et 
al., 2010). 
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Fear of falling can be evaluated using the Activities-specific Balance Confidence (ABC) 
scale, which has been validated for use in PD and HD. It is known that people sense their own 
instability before doctors can detect that physically. Falls due to syncope are thought to be 
uncommon in PD (Boonstra et al., 2008). ABC is a measure of balance confidence in which 
individuals verbally rate their confidence on a scale of 0% (not confident) to 100% 
(completely confident) in performing a series of 16 balance-challenging tasks of daily living. 
Balance confidence is low in recurrent fallers with HD (48,9%) (Goldberg et al., 2010) and 
PD (Boonstra et al., 2008). 
The Timed Up and Go (TUG) test is a clinical balance and mobility test, such as the Berg 
Balance scale. They are a measure of dynamic balance and functional mobility; TUG is the 
time taken to rise up from the seated position, walk 3 m at “comfortable and safe” walking 
speed, turn around, and walk 3 m to return to the seated position. TUG scores ≥ 14 are 
associated with an increased risk for recurrent falls in HD patients (Goldberg et al., 2010). 
Functional Reach (FR) is a reliable measure of anticipatory balance control and margin of 
stability. FR is the maximum distance one can reach forward beyond arm’s length while 
maintaining a fixed base of support in standing, and is measured with a yardstick affixed to 
the wall at the level of the acromion (Rao et al., 2009). 
Unified Huntington’s Disease Rating Scale (UHDRS) is a standardized clinical rating scale, 
that measures motor, cognitive, and behavioral function in HD, preceded by a history and 
medication scheme (Roos, 2010). Example of items: gait, tandem walk, and retropulsion 
(from 0 – normal, to 4 – maximum disability, each; for a total possible of 12) (Goldberg et al., 
2010). 
More studies are needed to develop a clinical instrument that is fast, cheap, and allows short-
interval assessment. 
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3.8. Treatment approaches 
 
3.8.1. Parkinson’s disease 
Gait and balance problems in PD tend to be perceived as being “untreatable”, but there are 
various therapeutic options (Bloem and Geurts, 2008). 
The main options are: pharmacotherapy, neurosurgery and physiotherapy, with the last two 
gaining more and more importance. Various studies highlighted that they may adversely 
affect balance and gait in PD (Boonstra et al., 2008). 
 
3.8.1.1. Pharmacotherapy 
Clissold et al. (2006) study showed that, although the proportion of “mid-line” motor 
disability increases with time, these deficits do not become unresponsive to levodopa. For 
instance, it can reduce the frequence of FOG episodes (Bloem and Geurts, 2008). 
However, levodopa may also adversely affect gait or balance control, leading to an increased 
risk of fall-related fractures (e.g., hip fractures), because of some adverse effects, such as 
violent dyskinesias or drug-induced orthostatic hypotension, or simply because patients on 
levodopa are more mobile and more prone to fall (Almeida et al., 2007). Falls occur despite 
maximal treatment with levodopa, confirming that axial disability in late stage PD is largely 
dopa-resistent (likely due to extranigral and nondopaminergic brain lesions – unlike the 
appendicular movements, which appear to be controlled by separate dopaminergic neural 
systems) (Boonstra et al., 2008). 
A new approach is methylfenidate (as mentioned previously), which can decrease fall risks in 
community dwelling older adults, by increasing availability of striatal dopamine or by 
improving attention, and improve gait and FOG in PD (Auriel et al., 2006). 
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3.8.1.2. Stereotatic neurosurgery: deep brain stimulation 
PD symtoms can be improved when electrodes are implanted in deep brain structures and 
electrical stimulation is delivered chronically at high frequency (＞100 Hz). Chronic electrical 
stimulation of deep neural structures is called deep brain stimulation (DBS). During DBS, 
these symptoms are improved by different network mechanisms operating at multiple time 
scales: locomotion takes more hours to improve than rest tremor, as locomotion (an axial 
symptom) improvement may involve a delayed plastic reorganization and rest tremor (a distal 
symptom) an instantaneous desynchronization of neural activity in subcortical structures, like 
subthalamic necleus (STN). Desynchronization and plasticity changes are two mechanisms 
that are believed to underlie the symptoms (Beuter and Modolo, 2009). 
DBS reduces symptoms efficiently in eligible subjects, but its underlying physiological 
mechanisms are still unclear. Latencies for improvement onset when DBS is turned “on” vary 
across symptoms (seconds to hours), long-term efficient reduction in symptoms differs across 
signs (months to years) suggesting strongly that qualitatively different mechanisms are at 
work (Beuter and Modolo, 2009). 
Bilateral STN stimulation is an effective treatment for PD, especially for appendicular 
symptoms that responded well to levodopa preoperatively. However, the effects of STN 
stimulation on axial motor signs remain debatable (Boonstra et al., 2008). It has been 
suggested that medication and deep brain surgery may affect axial mobility deficits by acting 
on different neural systems; at least some of the effect of STN stimulation may act via 
“downward” projections onto the PPN (Gan et al., 2007). 
Locomotion involves a large network of neuronal structures, requiring more complex 
modulation. Synaptic reorganization may be due to a gradual modification of synaptic 
weights in structures down-stream from the STN, in which axonal activation occurs at the 
same frequency as DBS. As DBS in the STN, pedunculopontine nucleus (PPN), or globus 
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pallidus internal (GPi) is effective in improving locomotion, DBS of subcortical structures 
induces a gradual reorganization of synaptic weights in efferent structures, like the cortex. 
This supports the hypothesis that DBS modulates plasticity. DBS normalizes cortical activity 
in several areas: supplementary motor area, premotor cortex, and primary motor cortex. It 
means that electrical stimulation of deep structures (STN or GPi) may have powerful effects 
on cortical plasticity (Beuter and Modolo, 2009). 
Desynchronization is equivalent to increasing cortical inhibition, which is defective in PD 
patients. To achieve the full potential of brain stimulation in PD, it will be needed to minimize 
invasiveness, optimize parameter adjustments, and reduce the cost of the procedure (Beuter 
and Modolo, 2009). 
There are increasing concerns that deep brain stimulation may worsen axial mobility, 
sometimes as an immediate adverse effect of surgery, but also as a longterm complication. 
This inconsistent response was found in Gan et al., 2007, study. Another particular worry is 
the development of new gait and balance deficits several years after surgery, even in the face 
of persistent beneficial effects on appendicular motor control (Boonstra et al., 2008). 
It has been speculated that variability in electrode placement can explain the inconsistent 
effects on axial mobility across patients. It could be that misplaced electrodes project 
unintentionally to the PPN, which, when stimulated at high frequencies, worsens gait and 
balance. On the basis of a Moreau et al. study, the authors proposed a two-staged STN 
frequency optimization: 130 Hz during the initial years of STN stimulation; and 60 Hz (at a 
higher voltage) after gait disorders have become manifest (Boonstra et al., 2008). 
Direct PPN stimulation is also possible to treat severe PD. It can improve axial symptoms 
directly postoperatively, and this persisting for 6 months. However, an extended follow-up is 
needed to evaluate long-term effects, as well as further research to investigate the effects in 
more detail and to study the effects of electrode (mis)placements (Ferraye et al., 2010). 
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There are recent DBS procedures targeting multiple structures, like simultaneous implantation 
of electrodes in the STN and PPN. PPN stimulation is complementary to STN stimulation, 
providing greater gait improvement than STN stimulation alone, especially in the advanced 
stages of the disease. However, implanting double electrodes on each side of the brain appears 
highly invasive and poses ethical problems (Beuter and Modolo, 2009). 
 
3.8.1.3. Physiotherapy 
Visual feedback is really important to compensate for motor disabilities in PD (reminding the 
perceptual cause for FOG), therefore physiotherapy has a huge potential in the treatment 
(Boonstra et al., 2008). Many patients with PD receive physiotherapy to alleviate symptoms 
of the disease, using treatments such as cueing and different forms of exercise. 
External cues can raise small but significant improvements in clinical gait and balance scores, 
FOG severity, gait speed and step length, and timed balance tests. Rhythmic auditory 
stimulation may improve gait, persisting 2 to 15 min after cueing, suggesting some degree of 
retention (Boonstra et al., 2008). 
However, cueing can also have adverse affects. Arias and Cudeiro (2008) study showed that 
RAS can differentially affect freezers and nonfreezers, as RAS increased the step length for 
nonfreezers, but produced the opposite effect for freezers; that study also showed that visual 
cueing may adversely affect gait, depending on disease severity: falls may paradoxically 
increase when patients receive cueing treatment, because mobility improves and also because 
the cueing may distract patients from paying attention to environmental hazards. As a result, 
cueing should not be prescribed as a universal treatment, but should be carefully tailored to 
specific factors such as disease severity and individual symptomatology (Boonstra et al., 
2008). 
Gait disorders in Parkinson’s and Huntington’s diseases 
47 
 
Another concern is whether cueing will benefit patients in daily life with its complex 
situations, as it does in the lab. Some studies showed that auditory cues helped to improve 
walking speed during a dual task situation, whereas somatosensory cues had no effect, and 
visual cues had a negative effect (Boonstra et al., 2008). 
There is increasing attention for the possible beneficial effects of physical exercise in PD. 
Physical functioning, balance, gait speed, strength and health-related quality of life improve 
for people with PD after a physical exercise intervention. Exercise therapy may also lead to a 
reduction in FOG. However, there is insufficient evidence to support that physical exercise is 
beneficial for reducing falls or depression (Boonstra et al., 2008). 
Muscle rigidity is a predominant feature of PD.  Therefore, physiotherapy strategies that are 
able to reduce muscle stiffeness and increase plantar-flexor power may be of benefit for PD 
patients and possibly improve their gait (Svehlik et al., 2009). 
Treadmill training may be one way to safely exercise patients with PD: because supervision is 
present and because a safety harness can prevent actual falls. Herman et al. (2007) study has 
shown that treadmill training can improve gait in PD. An alternative and more enjoyable way 
of exercise training is dancing: Hackney et al. (2007) study showed that tango dancing (20 
sessions) benefits patients with PD. 
The core treatment goals for physiotherapy includes: transfers, posture, reaching and 
grasping, balance, gait, and physical capacity. Important approaches are: cueing strategies to 
improve gait, cognitive movement strategies to improve transfers, exercises to improve 
balance, and training of joint mobility and muscle power to improve physical capacity 
(Boonstra et al., 2008). 
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3.8.2. Huntington’s disease 
There is no cure to HD. Management should be multidisciplinary and is based on treating 
symptoms with a view to improving quality of life. Chorea is treated with dopamine receptor 
blocking or depleting agents. Medication and non-medical care for depression and aggressive 
behavior may be required (Roos, 2010). 
Although many signs and symptoms can be treated, it is not always necessary to do so. The 
patient’s limitations in daily life determine whether or not drugs are required. Very little 
evidence is available about the drug or the dosage to prescribe for any signs and symptoms. 
Drug treatment is, therefore, individualized and based on expert opinion and daily practice. 
Treatment consists of drug prescription and non-medication advice. Surgical treatment does 
not play an important role in HD (Roos, 2010). 
 
3.8.2.1. Motor signs 
Hyperkinesia (chorea) is treated with dopamine receptor blocking or depleting agents. Most 
commonly used drugs (table 1) are typical or atypical neuroleptics (dopamine receptor 
blocking) and tetrabenazine (dopamine depleting) (Roos, 2010). An extensive review of all 
medication is given by Bonelli and Wenning (2006) and Bonelli and Hofmann (2007). 
Clozapine and olanzapine are atypical neuroleptics. Both have an antichoreatic effect. 
Clozapine requires white cell control in the blood and is less practical than olanzapine. The 
most frequently reported side effects are weight increase and anti-depressive effects. 
Prescribing quetiapine, zotepine, ziprasidone, and risperidone is also accepted (Roos, 2010). 
However, only tetrabenazine, a dopamine depleting drug, has been shown in a controlled trial 
to significantly reduce chorea (Huntington Study Group, 2006; Jankovic and Clarence-Smith, 
2011). The most common side effects are depression and sedation. 
 
Gait disorders in Parkinson’s and Huntington’s diseases 
49 
 
Tiapride Max 600 mg 
Olanzapine Max 20 mg 
Tetrabenazine Max 200 mg 
Pimozide Max 6 mg 
Risperidone Max 16 mg 
Fluphenazine Max 10 mg 
(drug dosages vary individually; here maximal dosages are given) 
Table 1: Drug treatment for chorea. 
 
Pridopidine is an experimental drug candidate belonging to a class of agents named dopidines. 
Dopidines are a new class of pharmaceutical compounds that act as dopaminergic stabilizers, 
enhancing or counteracting dopaminergic effects in the central nervous system, and 
normalizing dopaminergic neurotransmission. They have a dual mechanism of action, 
displaying functional antagonism of subcortical dopamine type 2 (D2) receptors as well as 
strengthening of cortical glutamate and dopamine transmission. Dopidines are, therefore, able 
to regulate both hypoactive and hyperactive functioning in areas of the brain that receive 
dopaminergic input, like cortical and subcortical regions. This potential ability to restore the 
cortical–subcortical circuitry to normal suggests that dopidines may be able to improve 
symptoms associated with HD (Feigin, 2011). 
In Feigin (2011) studies, pridopidine was safe and well tolerated. They also suggest that 
pridopidine might benefit features of HD for which there are currently no treatments (eye 
movements, hand coordination, dystonia, and gait or balance problems). Future trials will be 
needed to confirm these potential effects, and to investigate whether functional benefits 
accompany the motor improvements. Moreover, since 90 mg dose was well tolerated, higher 
doses could be tried in future trials. 
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Drug treatment for hypokinesia has been tried using antiparkinsonian drugs, but almost 
always with very disappointing results. Therefore, in practice, they are not prescribed (Roos, 
2010). 
No drug is available with any neuroprotective or disease-delaying effect. Disease modifying 
drugs are developed, but not available. Also embryonic cell implants, still under study, are not 
proven treatment options at the moment (Roos, 2010; Feigin, 2011). 
A well tolerated drug that produces even small benefits for patients would be a very welcome 
addition to the currently available treatments for this debilitating disorder (Feigin, 2011). 
Surgical intervention to treat chorea has been described in only a few cases. Deep brain 
stimulation has a place in other movement disorders like PD, but not in HD. 
 
3.8.2.2. Psychiatric, cognitive and behavioral signs 
As depression and aggressive behavior are the most devastating to family life, the majority of 
drugs are prescribed for these signs (table 2). Non-medical interventions available are: 
physiotherapy, occupational therapy, speech therapy, dietician, psychologist, social worker, 
and nurse (Roos, 2010; Jankovic and Clarence-Smith, 2011). 
Medical and non-medical treatment must be individually tailored, as the symptoms and signs 
differ by person and over time. Ideally treatment of patients and their families should be 
organized by a multidisciplinary team. 
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Depression Aggression 
Citalopram Max 60 mg Citalopram Max 60 mg 
Fluoxetine Max 60 mg Sertraline Max 200 mg 
Mirtazapine Max 45 mg Olanzapine Max 20 mg 
Valproinezuur Max 2000 mg Dipiperon Max 360 mg 
Carbamazepine Max 1600 mg Haloperidol Max 10 mg 
(drug dosages vary individually, here maximal dosages are given) 
Table 2: Drug treatment for depression and aggression. 
 
A better understanding of the HD pathophysiology will surely lead to drug development to 
interfere in the pathological process. We consider of major importance the development of 
effective treatment strategies aimed to reduce falls in HD, therefore more studies are needed. 
 
3.9. Quality of life 
PD is an incapacitating disease that negatively affects the quality of life for many reasons, 
such as: the presence of axial disability, gait disorders (discussed above), balance impairment, 
falls and fall-related injuries. 
The negative impact of gait disorders on quality of life is very important, due to the resultant 
immobility, loss of independence and the risk of falling. Falls in general and in PD in 
particular may lead to injuries, hip fractures, fear of falling, and restriction of activities that in 
turn contribute to institutionalization, loss of independence, and increased mortality 
(Hausdorff, 2009). However, fall rates tend to decrease with disease progression, because 
patients become increasingly immobilized. 
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Scheme 3: Clinical impact of falls in patients with Parkinson’s disease (adapted from 
Hausdorff, 2009). 
 
Episodic gait disorders are particularly incapacitating because patients cannot adjust their 
behavior to these paroxysmal walking problems. A good example is FOG, which is an 
important cause of falls and injures, because of its sudden and unpredictable nature.  FOG not 
only hinders efficient locomotion but also affects quality of life beyond gait and mobility 
(Moore et al., 2007). Therefore, special attention should be given to FOG in the treatment of 
patients with PD. 
Some studies associated FOG with falls, loss of independence and depression in patients with 
PD (Giladi and Hausdorff, 2006). 
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The aim of Moore et al. (2007) study was to examine the relationships between severity of 
FOG and quality of life in PD patients, based on the impression that FOG episodes are 
embarrassing when they occur in public and are a common cause for patients to avoid social 
interactions. It has not only mobility effects, but also psychological. In that study, FOG was 
found to have a direct effect on quality of life, beyond its effect on gait and mobility, which 
means that FOG has an added impact above falls and loss of mobility. Several explanations 
can be proposed: as an episodic event, FOG frequently catches the patient in the most 
uncomfortable and unpleasant situation, showing lost of control with regard to their own 
mobility, which is one of the most important patients’ fears; another aspect is its social 
consequences, as FOG episodes are frequent in crowded situations (like in the theater) and in 
time restricted situations (like crossing the street), leading to much embarrassment and 
frustration, with emotional consequences. Those mental aspects of FOG, like emotional, 
cognition and communication dimensions, have an impact on patients’ quality of life above 
the mobility aspects. Also FOG episodes can have a significant effect on the caregiver’s 
quality of life. Here we can conclude that there is a clear need to assess and treat all those 
FOG consequences, as an example using behavioral cues (Moore et al., 2007). Men and 
women are no different (Ho and Hocaoglu, 2011). 
The profound impact on HD patients’ physical and psychological well-being has been showed 
through data from generic quality of life questionnaires. On the other hand, interview studies 
allow patients to freely describe the impact of the disease, and play an important role in 
providing a meaningful understanding of patients’ perspective on their own well-being (Ho 
and Hocaoglu, 2011). 
In HD, a functional consequence of gait and balance impairments is increased risk for falls, as 
variability in stride length and step time is an established marker of fall risk (Delval et al., 
2006). Thus, quantitative examination of gait may be important in the identification of 
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individuals in the early stages of the disease, which may be at risk for falls later, with 
devastating consequences. Compared to nonfallers, fallers showed significantly higher scores 
for chorea, bradykinesia and aggression, as well as lower cognitive scores (Grimbergen et al., 
2008). 
As a result, contributing factors for falls include a combination of “motor” deficits (mainly 
gait bradykinesia, stride variability and chorea, leading to excessive trunk sway), as well as 
cognitive decline and perhaps behavioral changes (Grimbergen et al., 2008). 
The influence of motor disturbances on activities of daily life progresses over time. The 
presence of hyperkinesia and hypokinesia results in difficulties in walking and standing, and 
frequently leads to an ataxic gait and frequent falls. Furthermore, daily activities such as 
getting out of bed, taking a shower, dressing, toileting, cleaning the house, cooking and eating 
become more and more difficult. Depending on the kind of work the patient does, motor signs 
will sooner or later interfere with performance, even if psychiatric and cognitive changes are 
still in the background (Roos, 2010). 
The Ho and Hocaoglu (2011) study investigated how HD affects the experience of everyday 
life, in order to understand how the concerns change throughout the trajectory of illness from 
pre-clinical to end-stage HD. There appeared to be four phases of HD marked by different 
profiles of HD impact: the pre-HD stage, with emotional, social and self concerns; the stages 
1 and 2, with physical/functional and cognitive issues, in recognition and adaptation to the 
emergence of concrete HD symptoms; the stages 3 and 4, a period of stability in the overall 
scheme of disease progression; the stage 5, with physical/functional concerns, lack of 
cognitive concerns due to the cognitive impairment, and persistence of emotional, social and 
self concerns. 
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That study also provides an informed basis for the long-term management of health and well-
being in HD, and the development of interventions across the spectrum of HD stages (Ho and 
Hocaoglu, 2011). 
The progression of the disease leads to a complete dependency in daily life, which results in 
patients requiring fulltime care, and finally death. The most common cause of death is 
pneumonia, followed by suicide (Grimbergen et al., 2008). 
Assessing quality of life in movement disorders’ patients is very important, because losing 
control of one of the most fundamental tasks of motor behavior, such as gait and locomotion, 
is incredibly debilitating. 
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4. Discussion and Conclusions 
This review highlights the questions related to gait disorders in movement disorders to spark 
an interest and motivate future investigations, like other reports that would describe changes 
in gait among PD or HD patients and in other populations. 
There are many different types of gait disorders in both PD and HD. According to the 
majority of the authors, FOG is the most disabling gait feature in PD. However, in HD there is 
not a consensus and opinions diverge: decreased gait velocity, decreased stride length, 
decreased cadence, disordered temporal control of gait, and greater variability in spatial and 
temporal measures are the most common gait features. 
Considering the pathophysiological mechanisms of PD and HD, related to the circuits of the 
basal ganglia, they result both from the basal ganglia malfunction. The first one because of 
sunstantia nigra pars compacta depletion, and the second one being the consequence of the 
striatum degeneration. Their manifestations are, therefore, opposed: PD is a hypokinetic 
disease and HD is a hyperkinetic disease. Nevertheless, they have some gait features in 
common, such as increased gait variability or decreased stride length. 
PD is not a simple disease of motor control. It is becoming increasingly apparent that this is a 
complex neurodegenerative process that affects multiple systems, deteriorating at different 
rates, and controlled by distinct neural pathways. The neural networks and other pathologic 
mechanisms responsible for the PD gait alterations overlap, but at the same time, they are also 
quite distinct. Stride length, gait variability (mild PD), and fractal scaling (advanced PD) are 
all altered in PD. A therapy that is able to address and restore all these three aspects of gait 
may prove to be the most optimal. Key targets for new research include development of 
improved treatment strategies, including both pharmacotherapy (aimed at more than just 
dopaminergic motor circuitries), stereotactic surgery (optimizing STN stimulation and 
defining new targets such as the PPN), and physiopherapy. 
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PD and HD are very different, but at the same time very similar. Both affect gait severely, and 
this is the most disabling manifestation. However, cognition is differently affected, with HD 
being the worst. As a result, PD patients have a better capacity to deal with the gait disorders 
and to solve related problems, whereas HD patients have concentration deficits and cognitive 
impairments that affect their skills to face the disease. There is also a difference in the 
therapeutic opportunities between PD and HD, with HD patients having fewer chances to 
choose their treatment. 
Among patients with PD, 53% of fallers expressed a fear of falling, compared to only 15% in 
the HD group of patients, in the Grimbergen et al. (2008) study. Indeed, fallers with HD 
realized that their balance was disturbed, but as there was a low incidence of severe injuries, 
and a general indifference to serious consequences, they tended to ignore it more than PD 
patients. 
We leave the challenge of unrevealing the gait and clinical movement analysis research 
priorities, saying only that gait analysis is an effective tool in the clinical decision making 
process for improving treatment outcome in individuals, an effective functional outcome 
measure and an accurate, precise and valid method of quantifying movement. 
Indeed, we confirmed that gait disorders are tremendously important features of PD and HD, 
affecting deeply the patients’ life and well-being: somewhere in the course of the disease 
patients have to stop their normal lives because gait becomes progressively more affected, 
with increased instability, fear of falling and difficulties in dealing with daily tasks and 
demands; the social and functional parts of their lives are the most affected, therefore there is 
still a need to study and to analyze them. 
In the last years, many approaches developed, trying to deal with those decisive features, 
which helped to minimize some of the unwanted consequences of the diseases, like the 
independence loss. However, this is something that will certainly occur in the normal course 
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of the disease, even though nowadays we have the possibility to delay it. As a result, there is a 
need to develop new or even already known approaches that could help improving the impact 
of those features in daily patients’ lives. 
In view of the PD treatment, physiotherapy seems to be the most promissory way of 
management, since pharmacotherapy is very limited and DBS is really expensive. In HD, the 
most recent drugs do not affect gait in particular, but only the choreatic movements, thus 
more non-medical approaches are needed with proved efficacy. 
We consider that gait is a decisive factor in the management of patients, since when injured it 
is very disabling and embarrassing, being the most obvious feature of disease allocation. 
Indeed, patients with gait disorders become more exposed to the environment, more fragile 
and insecure. Achieving a gait improvement is really important, as it may restore some 
independence and quality of life. That is also the desire of the patients, helping them to gain 
the confidence they lost. Contributing to the patients’ happiness and well-being is one of our 
most important goals. 
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